



PB 24 of 2013

National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2013

National Health Act 1953

I, ADRIANA PLATONA, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953*.

Dated 22 April 2013

ADRIANA PLATONA

First Assistant Secretary (Acting)
Pharmaceutical Benefits Division
Department of Health and Ageing

1 Name of Determination

- (1) This Determination is the *National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2013*.
- (2) This Determination may also be cited as PB 24 of 2013.

2 Commencement

This Determination commences on the day after it is registered.

3 Definitions

In this Determination:

Act means the *National Health Act 1953*.

adjusted approved ex-manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.

supplementary disclosure cycle A has the same meaning as in regulation 37EB(2)(c) of the *National Health (Pharmaceutical Benefits) Regulations 1960*.

unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act.

weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.

4 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%

For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.

5 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%

For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.

6 Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%

For paragraph 99ADB(4) of the Act, the adjusted approved ex-manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.

7 Reduction Day

For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in a supplementary disclosure cycle A with a data collection period ending at the end of 31 January 2013 which is mentioned in Schedule 1 or 2 has a reduction day of 1 August 2013.

Schedule 1

Brands of pharmaceutical items – unadjusted price reduction is at least 10%

Column 1	Column 2				Column 3
Item	Brand of Pharmaceutical Item				Weighted average disclosed price
	Drug	Form	Manner of administration	Brand	
1	Dexamethasone	Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL	Injection	Dexmethsone	6.77
2	Dexamethasone	Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL	Injection	Hospira Pty Limited	6.77
3	Dexamethasone	Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL	Injection	Dexmethsone	12.3
4	Dexamethasone	Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL	Injection	Hospira Pty Limited	12.3
5	Temozolomide	Capsule 100 mg	Oral	Orion Temozolomide	455.17
6	Temozolomide	Capsule 100 mg	Oral	Temodal	455.17
7	Temozolomide	Capsule 100 mg	Oral	Temizole 100	455.17
8	Temozolomide	Capsule 100 mg	Oral	Astromide	455.17

9	Temozolomide	Capsule 140 mg	Oral	Astromide	627.72
10	Temozolomide	Capsule 140 mg	Oral	Orion Temozolomide	627.72
11	Temozolomide	Capsule 140 mg	Oral	Temodal	627.72
12	Temozolomide	Capsule 140 mg	Oral	Temizole 140	627.72
13	Temozolomide	Capsule 20 mg	Oral	Astromide	106.25
14	Temozolomide	Capsule 20 mg	Oral	Temizole 20	106.25
15	Temozolomide	Capsule 20 mg	Oral	Orion Temozolomide	106.25
16	Temozolomide	Capsule 20 mg	Oral	Temodal	106.25
17	Temozolomide	Capsule 250 mg	Oral	Astromide	1081.44
18	Temozolomide	Capsule 250 mg	Oral	Temodal	1081.44
19	Temozolomide	Capsule 250 mg	Oral	Temizole 250	1081.44
20	Temozolomide	Capsule 250 mg	Oral	Orion Temozolomide	1081.44
21	Temozolomide	Capsule 5 mg	Oral	Temizole 5	36.14
22	Temozolomide	Capsule 5 mg	Oral	Astromide	36.14
23	Temozolomide	Capsule 5 mg	Oral	Orion Temozolomide	36.14

24	Temozolomide	Capsule 5 mg	Oral	Temodal	36.14
----	--------------	--------------	------	---------	-------

Schedule 2

Brands of pharmaceutical items – unadjusted price reduction is less than 10%

Column 1	Column 2				Column 3
Item	Brand of Pharmaceutical Item				Weighted average disclosed price
	Listed Drug	Form	Manner of administration	Brand	
1	Dexamethasone	Eye drops 1 mg per mL, 5 mL	Application to the eye	Maxidex	3.38
2	Dexamethasone	Tablet 4 mg	Oral	Dexmethsone	4.45
3	Dexamethasone	Tablet 500 micrograms	Oral	Dexmethsone	1.79

Note

1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*. See <http://www.comlaw.gov.au>.